Literature DB >> 11922753

Expression, purification, and isotope labeling of a gp120 V3 peptide and production of a Fab from a HIV-1 neutralizing antibody for NMR studies.

Michal Sharon1, Matthias Görlach, Rina Levy, Yehezkiel Hayek, Jacob Anglister.   

Abstract

Most human immunodeficiency virus type 1 (HIV-1) neutralizing antibodies in infected individuals and in immunized animals are directed against the third variable loop (V3) of the envelope glycoprotein (gp120) of the virus. This loop plays a crucial role in phenotypic determination, cytopathicity (syncytium induction), and coreceptor usage of HIV-1. The human monoclonal antibody 447-52D was found to neutralize a broad spectrum of HIV-1 strains. In order to solve the solution structure of the V3MN peptide bound to the 447-52D Fab fragment by NMR, large quantities of labeled peptide and a protocol for the purification of the Fab fragment were needed. An expression plasmid coding for the 23-residue V3 peptide of the HIV-1MN strain (V3MN peptide, YNKRKRIHIGPGRAFYTTKNIIG) linked to a derivative of the RNA-binding domain of hnRNCP1 was constructed. The fusion protein attached to the V3 peptide prevents its degradation. Using this system, U-15N, U-13C,15N, and U-13C,15N, 50% 2H labeled fusion protein molecules were expressed in Escherichia coli grown on rich Celtone medium with yields of about 240 mg/liter. The V3MN peptide was released by CNBr cleavage and purified by RP-HPLC, giving final yields of 6-13 mg/liter. This expression system is generally applicable for biosynthesis of V3-related peptides and was also used to prepare the V3JR-FL. The 447-52D Fab fragment was obtained by a short enzymatic papain cleavage of the whole antibody. Preliminary NMR spectra demonstrate that full structural analysis of the V3MN complexed to the 447-52D Fab is feasible. This system enables studies of the same epitope bound to different HIV-1 neutralizing antibodies. Copyright 2002 Elsevier Science (USA).

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 11922753     DOI: 10.1006/prep.2001.1577

Source DB:  PubMed          Journal:  Protein Expr Purif        ISSN: 1046-5928            Impact factor:   1.650


  6 in total

1.  High-yield expression of isotopically labeled peptides for use in NMR studies.

Authors:  Darrin A Lindhout; Angela Thiessen; Dean Schieve; Brian D Sykes
Journal:  Protein Sci       Date:  2003-08       Impact factor: 6.725

2.  Efficient expression of isotopically labeled peptides for high resolution NMR studies: application to the Cdc42/Rac binding domains of virulent kinases in Candida albicans.

Authors:  Michael J Osborne; Zhengding Su; Vasanth Sridaran; Feng Ni
Journal:  J Biomol NMR       Date:  2003-08       Impact factor: 2.835

3.  Bcl-XL as a fusion protein for the high-level expression of membrane-associated proteins.

Authors:  Khang Thai; Jungyuen Choi; Carla M Franzin; Francesca M Marassi
Journal:  Protein Sci       Date:  2005-03-01       Impact factor: 6.725

4.  Expression, glycoform characterization, and antibody-binding of HIV-1 V3 glycopeptide domain fused with human IgG1-Fc.

Authors:  Qiang Yang; Cishan Li; Yadong Wei; Wei Huang; Lai-Xi Wang
Journal:  Bioconjug Chem       Date:  2010-05-19       Impact factor: 4.774

5.  A rapid method to attain isotope labeled small soluble peptides for NMR studies.

Authors:  Bernd W Koenig; Marco Rogowski; John M Louis
Journal:  J Biomol NMR       Date:  2003-07       Impact factor: 2.835

6.  Star nanoparticles delivering HIV-1 peptide minimal immunogens elicit near-native envelope antibody responses in nonhuman primates.

Authors:  Joseph R Francica; Richard Laga; Geoffrey M Lynn; Gabriela Mužíková; Ladislav Androvič; Baptiste Aussedat; William E Walkowicz; Kartika Padhan; Ramiro Andrei Ramirez-Valdez; Robert Parks; Stephen D Schmidt; Barbara J Flynn; Yaroslav Tsybovsky; Guillaume B E Stewart-Jones; Kevin O Saunders; Faezzah Baharom; Constantinos Petrovas; Barton F Haynes; Robert A Seder
Journal:  PLoS Biol       Date:  2019-06-17       Impact factor: 9.593

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.